An Assessment of the Heterogeneous Expression of Glypican-3 (GPC3) in Hepatocellular Carcinoma (HCC) in the Era of GPC3 as a Biomarker

被引：0
|
作者：
Cox, Brian [1 ]
Waters, Kevin [1 ]
Dhall, Deepti [1 ]
Larson, Brent [1 ]
Guindi, Maha [2 ]
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Beverly Hills, CA USA
来源：
MODERN PATHOLOGY | 2019年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1524
引用
收藏
页数：2
相关论文
共 50 条
  • [1] An Assessment of the Heterogeneous Expression of Glypican-3 (GPC3) in Hepatocellular Carcinoma (HCC) in the Era of GPC3 as a Biomarker
    Cox, Brian
    Waters, Kevin
    Dhall, Deepti
    Larson, Brent
    Guindi, Maha
    LABORATORY INVESTIGATION, 2019, 99
  • [2] Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis
    Sun, Bin
    Huang, Zhi
    Wang, Bi
    Yu, Yanglong
    Lin, Shihai
    Luo, Lei
    Wang, Yuzhu
    Huang, Zheng
    MEDICAL SCIENCE MONITOR, 2017, 23 : 850 - 855
  • [3] A correlation between Glypican-3 (GPC3) expression and the grading system in hepatocellular carcinoma
    Herlea, V.
    Procop, A.
    Pechianu, C.
    Mihai, M.
    Mustafa, E. Stoica
    Hortopan, M.
    Iorgescu, A.
    Andreoiu, O. -M.
    Varban, S.
    Popescu, I.
    VIRCHOWS ARCHIV, 2017, 471 : S134 - S134
  • [4] Glypican-3 (GPC3) expression in hepatocellular carcinomas and preneoplastic liver lesions
    Xiao, X. Y.
    Dubois, S.
    Tessiore, S.
    Degos, F.
    Belghiti, J.
    Allegretta, M.
    Guttmann, R.
    Bedossa, P.
    Paradis, V.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S107 - S107
  • [5] Immunological efficacy of glypican-3 (GPC3) peptide vaccine in patients with advanced hepatocellular carcinoma
    Tsuchiya, Nobuhiro
    Yoshikawa, Toshiaki
    Fujinami, Norihiro
    Saito, Keigo
    Shimomura, Manami
    Suzuki, Toshihiro
    Nosaka, Kazuto
    Shimizu, Hiroyasu
    Akazawa, Yu
    Charneau, Jimmy
    Sawada, Yu
    Endo, Itaru
    Nakatsura, Tetsuya
    CANCER SCIENCE, 2018, 109 : 276 - 276
  • [6] Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma
    Yasuda, Eisuke
    Kumada, Takashi
    Toyoda, Hidenori
    Kaneoka, Yuji
    Maeda, Atsuyuki
    Okuda, Seiji
    Yoshimi, Naoki
    Kozawa, Osamu
    HEPATOLOGY RESEARCH, 2010, 40 (05) : 477 - 485
  • [7] Expression of glypican 3 (GPC3) in embryonal tumors
    Saikali, Z
    Sinnett, D
    INTERNATIONAL JOURNAL OF CANCER, 2000, 89 (05) : 418 - 422
  • [8] Glypican-3 (GPC3) expression in human placenta: localization to the differentiated syncytiotrophoblast
    Khan, S
    Blackburn, M
    Mao, DL
    Huber, R
    Schlessinger, D
    Fant, M
    HISTOLOGY AND HISTOPATHOLOGY, 2001, 16 (01) : 71 - 78
  • [9] Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development
    Iglesias, Bibiana V.
    Centeno, Gloria
    Pascuccelli, Hector
    Ward, Flavia
    Peters, Maria Giselle
    Filmus, Jorge
    Puricelli, Lydia
    Joffe, Elisa Bal de Kier
    HISTOLOGY AND HISTOPATHOLOGY, 2008, 23 (11) : 1333 - 1340
  • [10] Proof of glypican-3 (GPC3) peptide specific CTLs infiltrating into tumor tissue derived from advanced HCC patient vaccinated with GPC3 peptide.
    Yoshikawa, Toshiaki
    Sakai, Mayuko
    Ofuji, Kazuya
    Takahashi, Mari
    Shimomura, Manami
    Sawada, Yu
    Nobuoka, Daisuke
    Nakatsura, Tetsuya
    CANCER RESEARCH, 2013, 73
12345